心脉医疗收盘上涨3.05%，滚动市盈率33.14倍，总市值148.26亿元

Group 1 - The core business of the company is the research, production, and sales of interventional medical devices for aorta and peripheral blood vessels [2] - The company reported a revenue of 332 million yuan for Q1 2025, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% year-on-year, with a gross margin of 69.61% [2] - The company's current stock price is 120.28 yuan, with a PE ratio of 33.14 and a total market capitalization of 14.826 billion yuan [1][3] Group 2 - The average PE ratio for the medical device industry is 59.32, with a median of 39.97, placing the company at the 65th position in the industry ranking [1][3] - The company has received several awards, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2] - The company has five institutional holders, including four funds and one brokerage, with a total holding of 324,900 shares valued at 2.9 million yuan [1]